EBMT 2023 Highlights Podcast

Robert van den Heuvel

Home > Haematology > EBMT 2023

European Group for Blood & Marrow Transplantation 23–26 April 2023 Paris, France

Featured articles

EBMT 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

EBMT 2023

14 May, 2023 20:09

ASCT or CAR T as first-line therapy for MM?

Presented By

Prof. Salomon Manier, Lille University Hospital, France

Conference

EBMT 2023

3 May, 2023 12:15

Ide-cel superior to standard therapies in triple-class-exposed RRMM

Presented By

Dr Paula Rodríguez-Otero, Clinica Universidad de Navarra, Spain

Trial

Phase 3, KarMMa-3

Conference

EBMT 2023

2 May, 2023 13:32

Online First

ASCT or CAR T as first-line therapy for MM?

Presented By

Prof. Salomon Manier, Lille University Hospital, France

Conference

EBMT 2023

3 May, 2023 12:15

DETERMINATION: Does one size fit all in multiple myeloma?

Presented By

Dr Hani Hassoun, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

DETERMINATION

Conference

EBMT 2023

3 May, 2023 12:12

Long-term success for CD19 CAR T-cell therapy in CLL

Presented By

Dr Emily Liang, University of Washington, WA, USA

Conference

EBMT 2023

3 May, 2023 12:09

Tacrolimus versus cyclosporine A in AML

Presented By

Dr Gesine Bug, Goethe University Frankfurt, Germany

Conference

EBMT 2023

3 May, 2023 12:07

Can molecular data improve prognostication in MDS patients undergoing HSCT?

Presented By

Dr Carmelo Gurnari, Cleveland Clinic, OH, USA

Conference

EBMT 2023

3 May, 2023 12:06

Ide-cel superior to standard therapies in triple-class-exposed RRMM

Presented By

Dr Paula Rodríguez-Otero, Clinica Universidad de Navarra, Spain

Trial

Phase 3, KarMMa-3

Conference

EBMT 2023

2 May, 2023 13:32

Quizartinib provides benefits on top of ASCT in AML

Presented By

Prof. Radovan Vrhovac, University Hospital Zagreb, Croatia

Trial

Phase 3, QuANTUM-First

Conference

EBMT 2023

2 May, 2023 13:29

Promising novel target for AML identified

Presented By

Dr Edmund Waller, Emory University, USA

Conference

EBMT 2023

2 May, 2023 13:27

Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT

Presented By

Dr Ayman Sayyed, University of Toronto, Canada

Journal

https://conferences.medicom-publishers.com/wp-content/uploads/2023/05/2_blinatumomab.mp3

Conference

EBMT 2023

2 May, 2023 13:26

Is ASCT a reasonable option in patients with invasive aspergillosis?

Presented By

Dr Olaf Penack, Charité University Hospital of Berlin, Germany

Conference

EBMT 2023

2 May, 2023 13:24

Medical Conferences

EBMT 2023

Featured articles

EBMT 2023 Highlights Podcast

ASCT or CAR T as first-line therapy for MM?

Ide-cel superior to standard therapies in triple-class-exposed RRMM

CONTENTS

Online First

ASCT or CAR T as first-line therapy for MM?

DETERMINATION: Does one size fit all in multiple myeloma?

Long-term success for CD19 CAR T-cell therapy in CLL

Tacrolimus versus cyclosporine A in AML

Can molecular data improve prognostication in MDS patients undergoing HSCT?

Ide-cel superior to standard therapies in triple-class-exposed RRMM

Quizartinib provides benefits on top of ASCT in AML

Promising novel target for AML identified

Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT

Is ASCT a reasonable option in patients with invasive aspergillosis?